Calgary, Alberta, September 4, 2025 - Universal Ibogaine Inc. (TSXV: IBO, in USA: IBOGF, in Germany FSE:JC4)  (“UI” or the “Company) is pleased to announce its intention to file, within 90 days, an application to Health Canada to initiate clinical trials (the Clinical Trial Application, or “CTA”) with the aim of investigating Ibogaine as a promising treatment for addiction for [...]

Calgary, AB – September 3, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that the existing Board of Directors of the Company (the “Board”) appointed two new Directors to join the Board, effective August 28, 2025, with one of the Board members [...]

Calgary, AB – July 16, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that Greg Leavens has resigned from his role as Chief Financial Officer and Corporate Secretary of the Company in order to pursue other opportunities. Nick Karos, CEO and Director, [...]

Calgary, AB – July 7, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that Ken Cranwill has resigned from the Board of Directors of the Company in order to focus on his other business ventures. Nick Karos, CEO and Director, noted “On [...]